February 23, 2021 Clinical Research/Diagn. M&A, Partnerships

Bio-Techne and Luminary Therapeutics Sign License Agreement for Use of Bio-Techne’s TcBuster for the Development of Luminary’s CAR-T Cell Therapies

FEBRUARY 23, 2021 MINNEAPOLIS, Feb. 23, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne’s proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing.   Under the terms of this agreement,... Read more

February 23, 2021 Clinical Research/Diagn. Lab Top-10 Liq. Handling & Robotics

PerkinElmer Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening

Company expands portfolio of SARS-CoV-2 testing solutions with rapid antigen test benchmarked against gold standard RT-PCR WALTHAM, Mass.–(BUSINESS WIRE)–Feb. 23, 2021– PerkinElmer, Inc. (NYSE: PKI) today announced the launch of the PerkinElmer® COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal (NS) or nasopharyngeal (NP) swab specimens. The lateral flow... Read more

February 23, 2021 Atomic Spectroscopy Clinical Research/Diagn. Lab Top-10

Thermo Fisher Scientific Announces Oncomine Clinical Research Grant 2021 Call for Submissions

Thermo Fisher Scientific Announces Oncomine Clinical Research Grant 2021 Call for Submissions CARLSBAD, Calif., Feb. 23, 2021 /PRNewswire/ — Thermo Fisher Scientific has opened a call for submissions for its Oncomine Clinical Research Grant program to support clinical research. The program aims to assist educational and independent research projects that exhibit excellence in molecular profiling... Read more

February 22, 2021 Clinical Research/Diagn. Licensing, IP, and Legal

Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)

Companion diagnostic can help guide treatment decisions in cases of NSCLC SANTA CLARA, Calif., February 22, 2021  Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC). PD-L1 IHC 22C3... Read more

February 19, 2021 Acad, Gov/Utilities Clinical Research/Diagn. Environ, Ag./Food & Bev Life Science Tools

Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases

TÜBINGEN, Germany–(BUSINESS WIRE)–February 19, 2021 — Illumina, Inc. (Nasdaq: ILMN) today announced an agreement with the Institute of Medical Genetics and Applied Genomics at the University Hospital of Tübingen to assess the value of whole-genome sequencing (WGS) as a first-line diagnostic test for patients with genetic diseases and familial cancer syndromes. Illumina will support the... Read more

February 18, 2021 Clinical Research/Diagn. Life Science Tools Product Launch

Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies

Kit marks first of multiple planned for 2021 aimed at COVID-19  SANTA CLARA, Calif., February 18, 2021  Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma. The kit, which... Read more

February 9, 2021 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Partners with Mindray on Clinical Chemistry Analyzers for use with Drugs of Abuse Immunoassays

Thermo Fisher Scientific Partners with Mindray on Clinical Chemistry Analyzers for use with Drugs of Abuse Immunoassays FREMONT, Calif., Feb. 9, 2021 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today announced a partnership with Mindray, a leading global developer, manufacturer and supplier of medical devices, to make available to customers two... Read more

February 8, 2021 Clinical Research/Diagn. Lab Top-10 Liq. Handling & Robotics Product Launch

Thermo Fisher Scientific Launches CE-IVD-Marked High Throughput COVID-19 Diagnostic Assay for Use On Its Automated Amplitude Platform

Thermo Fisher Scientific Launches CE-IVD-Marked High Throughput COVID-19 Diagnostic Assay for Use On Its Automated Amplitude Platform Applied Biosystems TaqPath COVID-19 High Throughput Combo Kit also receives Interim Order Authorization from Health Canada CARLSBAD, Calif., Feb. 8, 2021 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today launched its CE-IVD-Marked, Applied Biosystems TaqPath... Read more

February 3, 2021 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal M&A, Partnerships

Thermo Fisher Scientific and JW Therapeutics Announce CAR-T Partnership in China

Companies join forces in cell therapy applications and commercial-scale manufacturing WALTHAM, Mass., Feb. 3, 2021 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, has signed an agreement with JW Therapeutics, a leading cell therapy company, to ensure non-exclusive commercial access to Thermo Fisher’s Gibco CTS Dynabeads CD3/CD28. The agreement will support the clinical... Read more

January 28, 2021 Clinical Research/Diagn. M&A, Partnerships

Bio-Techne Announces Strategic Investment in Eminence

MINNEAPOLIS, Jan. 28, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced an initial minority strategic equity investment in Changzhou Eminence Biotechnology Co., Ltd. (“Eminence”).  Eminence will use the financing proceeds to expand its manufacturing capacity and increase the... Read more